Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 6/20 | 0.34 |
| ▸ | USP19 | O94966 | 4/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.33 |
| ▸ | ACP1 | P24666 | 6/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4285886 | 0.93 | HCRTR1 (0.34) | HCRTR2USP19HCRTR1ACP1OPRK1 | |
| SCHEMBL4292422 | 0.92 | USP19 (0.34) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4294441 | 0.91 | USP19 (0.36) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4295720 | 0.90 | USP19 (0.36) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4291191 | 0.89 | USP19 (0.38) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4283639 | 0.89 | HCRTR1 (0.35) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4291046 | 0.89 | USP19 (0.38) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4291112 | 0.88 | USP19 (0.33) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4290561 | 0.88 | USP19 (0.39) | HCRTR2USP19HCRTR1ACP1 | |
| SCHEMBL4292757 | 0.87 | HCRTR1 (0.35) | HCRTR2USP19HCRTR1ACP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR2 3136/4885USP19 1993/4885HCRTR1 3147/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | HCRTR2 3136/4885USP19 1993/4885HCRTR1 3147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.